Mouse Monoclonal HECTD2 Antibody

The HECTD2 antibody is a research tool designed to detect and study the HECT domain-containing E3 ubiquitin-protein ligase 2 (HECTD2), a member of the HECT family of E3 ubiquitin ligases. HECTD2 plays a critical role in the ubiquitination process, a post-translational modification that regulates protein degradation, localization, and activity via the ubiquitin-proteasome system. This enzyme contains a conserved HECT domain responsible for catalyzing the transfer of ubiquitin to substrate proteins, marking them for proteasomal degradation or functional modulation. HECTD2 is implicated in diverse cellular processes, including protein quality control, immune response regulation, and endoplasmic reticulum-associated degradation (ERAD). Dysregulation of HECTD2 has been linked to pathological conditions such as cancer, neurodegenerative diseases, and autoimmune disorders. For instance, studies suggest its involvement in tumor progression through interactions with oncogenic or tumor-suppressive pathways. The HECTD2 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation to investigate HECTD2 expression, localization, and interaction partners. Its applications extend to both basic research and translational studies, aiding in the exploration of HECTD2’s molecular mechanisms and therapeutic potential. Commercial HECTD2 antibodies are typically validated for specificity and sensitivity across human, mouse, or rat samples, enabling cross-species comparative analyses. Ongoing research aims to clarify its substrate specificity and physiological roles, positioning HECTD2 as a promising target for disease biomarker discovery or drug development.